Ohr Pharmaceutical Data Review Supports The Strong Potential Of Its Lead Drug OHR/AVR118 For Cachexia

November 26, 2009 by admin 

Ohr Pharmaceutical Inc. (OTCBB: OHRP) is developing OHR/AVR118 for treatment of cachexia based on technology acquired earlier this year from Advanced Viral Research Corp. OHR/AVR118 has shown excellent therapeutic efficacy and safety in human clinical trials in over 100 patients with applications for cachexia in Cancer and AIDS patients, as well as Rheumatoid Arthritis. OHR/AVR118 is a unique immunomodulator that affects the synthesis of chemokines and cytokines.

Source: Ohr Pharmaceutical Data Review Supports The Strong Potential Of Its Lead Drug OHR/AVR118 For Cachexia

Comments

Comments are closed.